Perry syndrome

Perry syndrome (also known as Perry disease or parkinsonism with alveolar hypoventilation and mental depression) is a rare, progressive neurodegenerative disorder caused by mutations in the DCTN1 gene, which encodes the largest subunit of the dynactin complex (p150Glued). This protein plays a critical role in intracellular transport along microtubules, and its dysfunction leads to accumulation of TDP-43 protein inclusions in affected neurons, particularly in the substantia nigra and brainstem respiratory centers. The disease primarily affects the central nervous system and manifests with four cardinal features: parkinsonism (rigidity, bradykinesia, and tremor that is often poorly responsive to levodopa), depression or apathy, significant and often unexplained weight loss, and central hypoventilation (reduced breathing drive originating from the brain). Symptoms typically begin in the fifth decade of life, with a mean age of onset around 49 years, though onset can range from the late 30s to the early 60s. The hypoventilation can be life-threatening, as patients may experience respiratory failure, particularly during sleep. Depression is frequently severe and may precede the motor symptoms. Tragically, suicide has been reported as a cause of death in a notable proportion of affected individuals. Perry syndrome follows a rapidly progressive course, with a mean disease duration of approximately 5 years from symptom onset to death. There is currently no disease-modifying treatment. Management is supportive and may include levodopa therapy (though response is typically limited or transient), antidepressant medications, nocturnal ventilatory support (such as BiPAP) for central hypoventilation, and nutritional support for weight loss. Close psychiatric monitoring is essential given the high risk of depression and suicidality. Genetic counseling is recommended for affected families.

Common questions about Perry syndrome